darunavir vs ranolazine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of darunavir and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Cardiac Disorders : ranolazine, ivabradine ↑ ranolazine ↑ ivabradine Co-administration is contraindicated due to potential for serious and/or life-threatening reactions.
Prezista
Ranexa
Darunavir is a medicine used to treat HIV. It belongs to a class of drugs called protease inhibitors and must be taken with ritonavir.
Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.
Darunavir is used to treat HIV-1 infection in adults and children 3 years and older. It must be taken with ritonavir and other HIV medicines. Darunavir helps to lower the amount of HIV in your body.
Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.
Darunavir is a protease inhibitor. It works by blocking an enzyme called protease that HIV needs to make copies of itself. This helps to slow down the spread of HIV in your body.
Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.
- • Diarrhea
- • Nausea
- • Rash
- • Headache
- • Abdominal pain
- • Dizziness
- • Headache
- • Constipation
- • Nausea
- Foetal Exposure During Pregnancy 1,150
- Drug Interaction 981
- Pain 889
- Emotional Distress 812
- Anxiety 811
- Death 816
- Myocardial Infarction 640
- Chest Pain 605
- Angina Pectoris 594
- Stent Placement 582
Darunavir can cause liver problems. Your doctor should check your liver before you start taking darunavir and during treatment. Tell your doctor right away if you have any signs of liver problems, such as yellowing of the skin or eyes.
Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.
Tell your doctor if you are pregnant or plan to become pregnant. The recommended dose during pregnancy is 600 mg twice daily with ritonavir 100mg and food. Women with HIV should not breastfeed because HIV can be passed to the baby through breast milk.
It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.
How to Read This darunavir vs ranolazine Comparison
darunavir is classified in the HIV Protease Inhibitor drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, darunavir has 4,643 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to darunavir stops your body from processing ranolazine correctly, which leads to high levels of the drug in your system. this can cause serious or life-threatening side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for darunavir or ranolazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.